Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration
Maureen G. Maguire(Penn Presbyterian Medical Center), Stuart L. Fine(University of Colorado Denver), Ebenezer Daniel(University of Pennsylvania), Gui‐Shuang Ying(Philadelphia College of Osteopathic Medicine), Frederick L. Ferris(National Institutes of Health), Cynthia A. Toth(Duke University), Glenn J. Jaffe(Duke University), Juan E. Grunwald(University of Pennsylvania), Daniel Martín(Townsville Hospital)
Cited by 702
Related Papers
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
|Ophthalmology|2012|1.7k
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|857
Diabetic Retinopathy Preferred Practice Pattern®
|Ophthalmology|2019|703
Adalimumab in Patients with Active Noninfectious Uveitis
|New England Journal of Medicine|2016|646